男性の健康：現在および新たな治療法の市場 (第2版)

Abstract

This complete re-evaluation of the Men's Health market focuses on the following prescription drug treatment segments:

• Men's Cancer
• Men's Sexual Dysfunction
• Men's Sexually Transmitted Diseases
• Men's Urinary Conditions
• Andropause

The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD's such as HIV, herpes, and genital warts. For each segment, revenues and forecasts are made by type of drug through 2010; competitive market share of the leading suppliers are estimated for 2005 and projected to 2010 based on likely market entrants and patent expiry; and a geographical breakdown (U.S. vs non-U.S.) is provided through 2010.

The report includes epidemiologic information on the various conditions (U.S. and worldwide) and reviews the issues and trends-business, clinical, regulatory, and social-that are shaping the future of this market.

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• History and Growth of the Men's Health Industry
• Male Anatomy
• Male Reproductive Physiology
• Male Demographics and Statistics

chapter Three: Men's Cancer

• Overview
  • Description of Cancers Affecting Men
  • Prostate Cancer
  • Testicular Cancer
  • Prevalence and Incidence
• Description of Products
  • Hormone Therapies
  • LHRH Analogs
  • Antiandrogens
  • Intermittent Hormone Therapy
  • Adjuvant Hormone Therapy
  • Chemotherapy Agents
  • Brachytherapy
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive analysis

chapter Four: Male Sexual Dysfunction

• Overview
  • Description of Sexual Disorders Affecting Men
  • Erectile Dysfunction
  • Ejaculation Disorders
  • Prevalence and Incidence
• Description of Products
  • Phosphodiesterase Type V Inhibitors (PDE-5 Inhibitors)
  • Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

chapter Five: Sexually Transmitted Diseases

• Overview
  • Description of Sexually Transmitted Diseases Affecting Men
  • Chlamydia
  • Genital Herpes
  • Genital Warts
  • Gonorrhea
  • HIV/AIDS
  • Syphilis
  • Prevalence and Incidence
• Description of Products
  • Antibiotics
  • Antiviral Therapies
  • Others
• Research and Development
  • Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive Analysis

chapter Six: Men's Urinary Conditions

• Overview
  • Description of Urinary Conditions Affecting Men
  • Benign Prostate Hypertrophy (BPH)
  • Prostatitis
  • Urinary Incontinence
  • Prevalence and Incidence
• Description of Products
  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Anticholinergics
  • Antispasmodics and Others
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  • Competitive Analysis

chapter Seven: Male Menopause or Andropause

• Overview
  • Description of Male Menopause
  • Prevalence and Incidence
• Description of Products
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
• Competitive Analysis

Chapter Eight: Issues and Trends Affecting the Men's Health Market

• Introduction
• Education and Awareness of Men's Health
• Office of Men's Health
• Changing Life Expectancy
• Diabetes and Sleep
• Early Detection and Screening of Prostate Cancer
• Blacks and Prostate Cancer
• Erectile Dysfunction and CAD
• Cosmetic Surgery
• Bladder Cancer Detection
• Lifestyle Changes and Prostate Cancer
• Effects of Testosterone Dosage on Behavior of Older Men
• Testosterone Replacement Therapy Decreases Fat and Increases Muscle
• Men of All Ages Respond to Building Muscle Mass with Testosterone Doses

Chapter Nine: Market Summary

• Overview
• Market Size and Forecast
  • World Market
  • Markets by Segments
• Competitor Analysis
• Market Outlook

chapter Ten: Corporate Profiles

• Introduction
• Current Market Leaders Profiles
• Abbott Laboratories
• Astellas Pharma Inc.
• ALZA Corporation
• AstraZeneca plc
• Bayer Corporation
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Eli Lilly & Company
• GlaxoSmithKline plc
• Merck & Company, Inc.
• Pfizer, Inc.
• Roche Group
• Sanofi-Aventis
• Takeda Chemical Industries, Ltd.
• TAP Pharmaceutical Products, Inc.
• Unimed Pharmaceuticals, Inc.
• VIVUS, Inc.
• Watson Pharmaceuticals, Inc.

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: The World Market for Men's Health Prescription Drugs 2003-2010
• Figure 1-1: Trending in the World Market Men's Health, 2003-2010

Chapter Two: Introduction

• Table 2-1: World Male Population by Selected Geographical Region 2005-2050
• Table 2-2: Life Expectancy at Birth by Selected Countries, 2000
• Table 2-3: United States Life Expectancy at Birth, 1990-2000, and Projections, 2005-2010
• Table 2-4: Estimated Male Prevalence of Selected Risk Behavior by Geographical Region, 2005
• Figure 2-1: Estimated Male Prevalence of Selected Risk Behavior by Geographical Region, 2005

chapter Three: Men's Cancer

• Table 3-1: Men's Cancer: Estimated World Incidence and Prevalence
• Figure 3-1: Men's Cancer: World Incidence
• Table 3-2: Research and Development in Men's Cancer Therapies (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 3-3: The World Market Men's Health: Men's Cancer Therapies by Product Type (Hormone Therapy, Chemotherapy) 2003-2010
• Figure 3-2: Trending in the World Market for Men's Cancer Therapies 2003-2010
• Table 3-4: The U.S. Market Men's Cancer Therapies 2003-2010
• Figure 3-3: Trending in the U.S. Market for Men's Cancer Therapies 2003-2010
• Table 3-5: The International (Non-U.S.) Market for Men's Cancer Therapies 2003-2010
• Figure 3-4: Trending in the International (Non-U.S.) Market for Men's Cancer Therapies, 2003-2010
• Table 3-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Cancer Therapies Estimated 2005 and Projected 2010
• Figure 3-5: Leading Suppliers Market Share of the World Market for Men's Cancer Therapies, 2005 and 2010

chapter Four: Male Sexual Dysfunction

• Table 4-1: Estimated World and U.S. Incidence and Prevalence of Male Sexual Dysfunction by Type (Erectile Dysfunction, Premature Ejaculation)
• Figure 4-1: World Prevalence of Men's Sexual Dysfunction
• Table 4-2: PDE-5 Inhibitor Comparison Chart
• Table 4-3: Research and Development in Men's Sexual Dysfunction (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 4-4: The World Market Men's Sexual Dysfunction Therapies by Product Type (PDE-5 Inhibitors and Others) 2003-2010
• Figure 4-2: Trending in the World Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-5: The U.S. Market for Men's Sexual Dysfunction Therapies 2003-2010
• Figure 4-3: Trending in the U.S. Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-6: The International (Non-U.S.) Market for Men's Sexual Dysfunction Therapies 2003-2010
• Figure 4-4: Trending in the International (Non-U.S.) Market for Men's Sexual Dysfunction Therapies 2003-2010
• Table 4-7: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Sexual Dysfunction Therapies Estimated 2005 and Projected 2010
• Figure 4-5: Leading Suppliers' Market Shares of the World Market for Men's Sexual Dysfunction Therapies, 2005 and 2010

chapter Five: Sexually Transmitted Diseases

• Table 5-1: Men's Sexually Transmitted Diseases: Estimated World Incidence
• and Prevalence for Men (in thousands)
• Figure 5-1: Men's Sexually Transmitted Diseases: World Incidence
• Table 5-2: Research and Development in Sexually Transmitted Disease Therapeutics (Product, Developer, Phase, Drug Class, Indication, Projected Approval Date for Phase III)
• Table 5-3: The World Market Men's Sexually Transmitted Disease Therapies by Product Type (Antibiotics, Antivirals, Others) 2003-2010
• Figure 5-2: Trending in the World Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Table 5-4: The U.S. Market Men's Sexually Transmitted Disease Therapies 2003-2010
• Figure 5-3: Trending in the U.S. Market for Men's Sexually Transmitted Disease Therapies, 2003-2010
• Table 5-5: The International (Non-U.S.) Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Figure 5-4: Trending in the International (Non-U.S.) Market for Men's Sexually Transmitted Disease Therapies 2003-2010
• Table 5-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Sexually Transmitted Disease Therapies Estimated 2005 and Projected 2010
• Figure 5-5: Leading Suppliers' Market Shares of the World Market for Men's Sexually Transmitted Disease Therapies 2005 and 2010

chapter Six: Men's Urinary Conditions

• Table 6-1: Estimated World Incidence and Prevalence for Men's Urinary
• Conditions (BPH and Urinary Incontinence; in thousands)
• Figure 6-1: Men's Urinary Conditions: World Prevalence
• Table 6-2: Research and Development in Urinary Condition Therapeutics (Product, Developer, Phase, Drug Class, Indication, Projected Approval Date for Phase III)
• Table 6-3: The World Market Men's Urinary Condition Therapies by Product Type (Hormone Therapy, Chemotherapy) 2003-2010
• Figure 6-2: Trending in the World Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-4: The U.S. Market for Men's Urinary Condition Therapies 2003-2010
• Figure 6-3: Trending in the U.S. Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-5: The International (Non-U.S.) Market for Men's Urinary Condition Therapies 2003-2010
• Figure 6-4: Trending in the International (Non-U.S.) Market for Men's Urinary Condition Therapies 2003-2010
• Table 6-6: Leading Suppliers' Revenues and Market Shares of the World Market for Men's Urinary Condition Therapies Estimated 2005 and Projected 2010
• Figure 6-5: Leading Suppliers Market Shares of the World Men's Urinary Condition Therapies Market 2005 and 2010

chapter Seven: Male Menopause or Andropause

• Table 7-1: Estimated World Incidence and Prevalence of Andropause (in thousands)
• Figure 7-1: World Prevalence of Andropause (Low and High Range)
• Table 7-2: Research and Development in Sexually Transmitted Disease Therapeutics (Product, Developer, Phase, Drug Class, Projected Approval Date)
• Table 7-3: The World Market for Andropause Therapies 2003-2010
• Figure 7-2: Trending in the World Market for Andropause Therapies 2003-2010 Table 7-4: The U.S. Market for Andropause Therapies 2003-2010
• Figure 7-3: Trending in the U.S. Market for Andropause Therapies 2003-2010
• Table 7-5: The International (Non-U.S.) Market for Andropause Therapies 2003-2010
• Figure 7-4: Trending in the International (Non-U.S.) Market for Andropause Therapies 2003-2010
• Table 7-6: Leading Suppliers' Revenues and Market Shares of the World Market for Andropause Therapies Estimated 2005 and Projected 2010

Chapter Eight: Issues and Trends Affecting the Men's Health Market

• Table 8-1: Relative Risk Related to Family History of Prostate Cancer

Chapter Nine: Market Summary

• Table 9-1: The World Market for Men's Health Prescription Drugs 2003-2010
• Table 9-2: The World Market for Men's Health Prescription Drugs by Segment (Men's Cancer, Sexual Function, Sexually Transmitted Diseases, Urinary Conditions, Andropause) 2003-2010
• Figure 9-1: Trending in the World Market for Men's Health Therapeutics 2003-2010
• Figure 9-2: Distribution of Revenues in the World Market for Men's Health Therapeutics by Product Type 2005
• Table 9-4: Leading Suppliers and Significant Segments of Participation 2005